Holen Sie sich die Stockscreener-App
32.09
0.37%
0.025
Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten
Supernus to acquire Sage Therapeutics stock for $8.50 per share By Investing.com - Investing.com UK
Supernus to acquire depression drugmaker Sage - MSN
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics - MSN
Supernus Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal - Yahoo Finance
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News - Benzinga
Supernus buys Sage Therapeutics for $561 million as Cantor holds rating - Investing.com Canada
Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus - Yahoo Finance
Are Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? - simplywall.st
SAGE to Be Acquired by Supernus Pharmaceuticals | SAGE Stock New - GuruFocus
Trading (SUPN) With Integrated Risk Controls - news.stocktradersdaily.com
Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal - whbl.com
Supernus Pharmaceuticals picks up embattled Sage Therapeutics - Mugglehead Magazine
Supernus Secures Sage With CVR-Supported Deal - insights.citeline.com
Supernus to Acquire Sage Therapeutics in $795M Deal - USA Herald
Saul Ewing-Led Supernus Inks Up To $795M Brain Health Deal - Law360
Deals of the day-Mergers and acquisitions - marketscreener.com
Supernus to acquire Sage Therapeutics for up to $795 million By Investing.com - Investing.com South Africa
Supernus enters depression drug market with up to $795 million Sage deal | Business Information & News | FE - Westlaw Today
Supernus To Acquire Sage: A Smart Move, Despite Both Pharmas' MDD Woes (NASDAQ:SUPN) - Seeking Alpha
Supernus Pharma's $795 Million Acquisition of Sage Therapeutics Boosts Shares - GuruFocus
Supernus’ $795 million bid sufficient for Sage - The Pharma Letter
Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know. - Barron's
Sage, following Setbacks, to sell to Supernus for $561M - BioPharma Dive
Supernus makes depression drug play with $795m Sage buyout - Yahoo Finance
Supernus enters depression drug market with up to $795 million Sage deal - Reuters
Supernus to acquire Sage Therapeutics for $8.50 per share in cash plus CVR - TipRanks
Supernus to buy Sage for up to $795 million - Axios
Transcript : Supernus Pharmaceuticals, Inc., Sage Therapeutics, Inc.M&A Call - MarketScreener
Supernus strikes deal to buy Sage Therapeutics - The Business Journals
After rebuffing Biogen, Sage pairs off with Supernus - pharmaphorum
Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus - BioSpace
Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million - inkl
Sage Therapeutics shares soar after supernus acquisition deal By Investing.com - Investing.com Canada
After brushing off Biogen, Mass. biotech firm finds buyer for $795M - NBC Boston
Maryland firm outbids Biogen for Sage Therapeutics - The Business Journals
Supernus Pharmaceuticals (SUPN) to Acquire Sage Therapeutics in $795M Deal - GuruFocus
Supernus Pharmaceuticals To Acquire Sage Therapeutics, Strengthening Its Neuropsychiatry Product Portfolio - MarketScreener
Sage Therapeutics Stock Soars 35% After Sale to Supernus Pharmaceuticals. What We Know. - Barron's
Biogen (BIIB) Gains from Supernus-Sage Therapeutics Acquisition - GuruFocus
Supernus to Acquire Sage Therapeutics (SAGE) for $8.50 Per Share - GuruFocus
Supernus Pharmaceuticals To Acquire Sage Therapeutics - citybiz
Supernus stock in focus as Sage agrees to buy (SAGE:NASDAQ) - Seeking Alpha
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio | SUPN Stock News - GuruFocus
Supernus to acquire Sage Therapeutics for up to $795 million - Investing.com
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio - GlobeNewswire
GAMMA Investing LLC Grows Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Holdings Cut by Rhumbline Advisers - Defense World
California State Teachers Retirement System Lowers Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Two Sigma Advisers LP Increases Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Two Sigma Investments LP - Defense World
Millennium Management LLC Trims Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus at Jefferies Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com South Africa
(SUPN) Trading Report - news.stocktradersdaily.com
Supernus at Jefferies Global Healthcare Conference: Strategic Insights - Investing.com
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Nuveen Asset Management LLC - Defense World
Supernus (SUPN) Partners with Jay Glazer for ADHD Awareness Series | SUPN Stock News - GuruFocus
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and R - GuruFocus
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals | SUPN Stock News - GuruFocus
Supernus Pharmaceuticals Partners with Jay Glazer for ADHD Awareness Series Featuring Insights from His Journey with Qelbree - Nasdaq
0.27%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):